Advances in the therapy of high-grade glioma at relapse: pegylated liposomal doxorubicin

References

• Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. I Neuropathol Exp. Neural. 61(3), 215–225 (2002).
   Google Scholar
• Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology and End Results (SEER) data, 1973–1991. Aburasu,g. 88(1), 1–10 (1998).
   Google Scholar
• •Gives a good overview of epidemiologic factors in high-grade glioma.
   Google Scholar
• Should SC, Burger PC, Mendeksohn DB et al Primary tumors of the brain and spinal cord. Butterworth-Heinemann, Boston, MA, USA, 51–54 (1997).
   Google Scholar
• Sawaya R. Extent of resection in malignant gliomas: a critical summary. I Neurooncol 42(3), 303–305 (1999).
   PubMedGoogle Scholar
• •Presents a nice discussion on pros and cons for complete resection in high-grade glioma.
   Google Scholar
• Fransen P, de Tribolet N. Surgery of supratentorial tumors. Curl: Opin. Oncol 5(3), 450–457 (1993).
   Google Scholar
• Stewart LA. Chemotherapy in adult high- grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311), 1011–1018 (2002).
   Google Scholar
• Stupp R, Dietrich PY, Ostermann Kraljevic S et al Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. j Clin. Oncol 20(5), 1375–1382 (2002).
   Google Scholar
• Wong ET, Hess KR, Gleason MJ et al Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol 17(8), 2572 (1999).
   Google Scholar
• ••Good metaanalysis providing basic datafor the design of clinical Phase II trial and their evaluation.
   Google Scholar
• Brandes AA, Fiorentino MV The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest. 14(6), 551–559 (1996).
   Google Scholar
• •Summarizes the role of chemotherapeutic options in recurrent high-grade glioma.
   Google Scholar
• DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: who benefits from adjuvant chemotherapy? Ann. Neurol 44(4), 691–695 (1998).
   Google Scholar
• •Summarizes data guiding chemotherapeutic interventions in high-grade glioma.
   Google Scholar
• Haroun RI, Brem H. Local drug delivery. Cun: Opin. Oncol 12(3), 187–193 (2000).
   Google Scholar
• Grant R, Liang BC, Slattery J, Greenberg HS, Junck L. Chemotherapy responsecriteria in malignant glioma. Neurology 48(5), 1336–1340 (1997).
   PubMedGoogle Scholar
• Kouloulias VE, Dardoufas CE, Kouvaris JR et al Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a Phase I/II trial. Clin. Cancer Res. 8(2), 374–382 (2002).
   PubMed Web of Science ®Google Scholar
• Halford S, Yip D, Karapetis CS et al. A Phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma. Ann. Oncol 12(10), 1399–1402 (2001).
   PubMed Web of Science ®Google Scholar
• Dvorak J, Zoul Z, Melichar B et al Pegylated liposomal doxorubicin in combination with hyperthermia in the treatment of a case of advanced hepatocellular carcinoma. J. Clin. Castroenterol 34(1), 96–98 (2002).
   Google Scholar
• Muggia F, Hamilton A. Phase III data on Caelyx in ovarian cancer. Eur. J. Cancer 37\(Suppl. 9), S15-18 (2001).
   Google Scholar
• Thomas AL, OByrne K, Furber L, Jeffery K, Steward WP. A Phase II study of caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer. Cancer Chemother. Phatmacol 48 (4), 266–268 (2001).
   Google Scholar
• Harrington KJ, Lewanski C, Northcote AD etal. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur. Cancer 37(16), 2015-2022 (2001).
   Google Scholar
• Judson I, Radford JA, Harris M et al Randomised Phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. Cancer37 (7), 870–877 (2001).
   PubMed Web of Science ®Google Scholar
• Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin. Cancer Res. 4(2), 499–505 (1998).
   Google Scholar
• Gabizon A, Martin E Polyethylene glycol- coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54\(Suppl. 4), 15–21 (1997).
   Google Scholar
• •Provides an overview of the rationale for using PEG-liposomal doxorubicin in solid tumors.
   Google Scholar
• Gabizon A, Goren D, Horowitz AT et al Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor bearing animals. Adv. Drug Deliv. 24,337–344 (1997).
   Web of Science ®Google Scholar
• Gabizon A, Chemla M, Tzemach D, Horowitz AT, Goren D. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. I Drug Target 3(5), 391–398 (1996).
   PubMed Web of Science ®Google Scholar
• Hosoda J, Unezaki S, Maruyama K, Tsuchiya S, Iwatsuru M. Antitumor activity of doxorubicin encapsulated in poly (ethylene glycol) -coated liposomes. Biol. Pharm. Bull. 18(9), 1234–1237 (1995).
   Google Scholar
• Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P Tissue distribution and therapeutic effect of iv. free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer73(5), 1478–1484 (1994).
   PubMed Web of Science ®Google Scholar
• Harris L, Winer E, Batist G, Rovira D, Navari R, Lee L. Phase III study of TLC D-99 (liposome encapsulated doxorubicin versus free doxorubicin in patients with metastatic breast carcinoma. Proc. Am. Soc. Clin. Oncol 17,474 (1998).
   Google Scholar
• Ranson MR, Carmichael J, OByrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter Phase II trial. j Clin. Oncol 15(10), 3185–3191 (1997).
   Google Scholar
• Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. I Neurosurg. 83(6), 1029–1037 (1995).
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Koukouraki S, Fezoulidis I et al High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in lioblastomas and in metastatic brain tumours. Br. Cancer83(10), 1281–1286 (2000).
   Google Scholar
• •Well-designed basic science study providing data about the accumulation of PEG-liposomal doxorubicin in glioblastoma.
   Google Scholar
• Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H. Chemosensitivity of glioma cells in vitro: a meta analysis. Cancer Res. Clin. Oncol 125(8–9), 481–486 (1999).
   Google Scholar
• •Provides the scientific basis for the use of PEG-liposomal doxorubicin in high-grade glioma.
   Google Scholar
• Voulgaris S, Partheni M, Karamouzis M, Dimopoulos P, Papadakis N, Kalofonos HP Intratumoral doxorubicin in patients with malignant brain gliomas. Am. J. Clin. Oncol 25(1), 60–64 (2002).
   Google Scholar
• Twentyman PR. MDR1 (P-glycoprotein) gene expression-implications for resistance modifier trials. .1. Nail Cancer Inst. 84(19), 1458–1460 (1992).
   Google Scholar
• Fabel K, Dietrich J, Hau P et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92 (7), 1936–1942 (2001).
   PubMed Web of Science ®Google Scholar
• Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin. Cancer Res. 4(6), 1567–1571 (1998).
   PubMed Web of Science ®Google Scholar
• Lyass 0, Uziely B, Ben-Yosef R et al Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer89(5), 1037–1047 (2000).
   Google Scholar
• Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a Phase II study of the Italian Sarcoma Group (ISG). AntiCancer Res. 20(1B), 485–491 (2000).
   Google Scholar
• Working PK, Dayan AD. Pharmacological- toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCO . Hum. Exp. Toxicol 15(9), 751–785 (1996).
   Google Scholar
• •Summarizes pharmacolocical and toxicological data on PEG-liposomal doxorubicin.
   Google Scholar
• Working PK, Newman MS, Sullivan T, Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. I Pharmacol Exp. Ther. 289(2), 1128–1133 (1999).
   Google Scholar
• Brada M, Hoang-Xuan K, Rampling R et al Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol 12(2), 259–266 (2001).
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J et al A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. BE j Cancer 83(5), 588–593 (2000).
   Google Scholar
• Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. j Clin. Oncol 17(9), 2762–2771 (1999).
   Google Scholar
• Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. j Clin. Oncol 20(5), 1383–1388 (2002).
   Google Scholar
• Burch PA, Bernath AM, Cascino TL et al A North Central Cancer Treatment Group Phase II trial of topotecan in relapsed gliomas. Invest. New Drugs18(3), 275–280 (2000).
   PubMed Web of Science ®Google Scholar
• Fine HA, Figg WD, Jaeckle K et al Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. j Clin. Oncol 18(4), 708–715 (2000).
   Google Scholar
• Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M. Thalidomide as an anti-angiogenic agent in relapsed gliomas. Neurooncol 51(1), 41–45 (2001).
   PubMedGoogle Scholar
• Rajkumar SV, Reid JM, Novotny PJ et al A randomized Phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. I Neurooncol 49(3), 255–261 (2000).
   PubMedGoogle Scholar
• Rosenthal MA, Gruber ML, Glass J et al Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme. Neurooncol 47(1), 59–63 (2000).
   PubMedGoogle Scholar
• Sanson M, Napolitano M, Yaya R eta] Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a Phase II study. I Neurooncol 50(3), 245–249 (2000).
   PubMed Web of Science ®Google Scholar
• Schmidt F, Wick W, Herrlinger U, Dichgans J, Weller M. Treosulfan chemotherapy for recurrent malignant glioma. I Neurooncol 49(3), 231–234 (2000).
   PubMedGoogle Scholar
• Ashby LS, Shapiro WR. Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a Phase II study. I Neurooncol 51(1), 67–86 (2001).
   PubMedGoogle Scholar
• Cloughesy TF, Filka E, Nelson G eta] Irinotecan treatment for recurrent malignant glioma using an every 3-week regimen. A117. I Clin. Oncol 25(2), 204–208 (2002).
   Google Scholar
• Robins HI, Chang SM, Prados MD et al A Phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study. Neum-Oncol 4(2), 109–114 (2002).
   PubMedGoogle Scholar